Cherwell publishes Cleanroom Decontamination Guide
Guide aims to help the operator understand the complex protocols and heavily regulated procedures associated with pharmaceutical cleanrooms.
Cherwell Laboratories, specialist suppliers of products for environmental monitoring, cleanroom bio-decontamination and process validation, has published a booklet titled, “The Pharmaceutical Lab’s Pocket Guide to Cleanroom Decontamination.”
The guide, which is available to download from Cherwell’s website, provides cleanroom operators and laboratory personnel with an overview of cleanroom decontamination technologies. The aim of the guide is to help the operator understand the complex protocols and heavily regulated procedures associated with pharmaceutical cleanrooms. The guide includes an overview of cleanroom disinfectants; decontamination techniques; decontamination devices and systems that deliver quicker, safer cleanroom decontamination.
The eBook starts with the background to cleanroom standards and regulations, including reference to ISO-14644 parts 1 and 2, as well as the EU Biocidal Products Regulations which are of great importance when choosing a biocide. Also covered is a summary of the different biocidal agents available, the different techniques you can employ to disinfect a cleanroom and points to consider when choosing the appropriate decontamination solution for your cleanroom.
Andrew Ramage, Cherwell Laboratories’ Microbiology Product Specialist comments: “This booklet will arm the user with clear and concise information to better understand why and how best to decontaminate a cleanroom. It will be especially useful for inexperienced and trainee operators trying to get to grips with working in that type of environment, and also act as a handy reminder to the basics for more experienced operators.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.